Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new policy for commercial coverage of its cfDNA Fetal RhD ...

When discussing the value of screening for 22q, the authors concluded that, “the PPV of cfDNA for 22q11.2DS is higher and the false positive rate is lower than that associated with other accepted ...

Natera's robust financial performance, driven by strong growth in its Women’s Health and Oncology segments, justifies its recent stock price surge and positive outlook. The company’s strategic ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly ...

Genetic testing company Natera (NASDAQ:NTRA). announced in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98 billion at the midpoint came ...

When Mara Varona was pregnant she decided to take a common prenatal blood test to screen for genetic conditions. It was part of a proactive approach she and her husband took to pregnancy. "We're just ...